T-Cell Engager
Beyond's analysis on T-Cell Engager
- — Abogen’s mRNA T‑cell engager deal with Novartis expands immunotherapy pipeline and validates its RNA platform
- — Abogen licenses its mRNA-encoded T-cell engager to Novartis, expanding the latter's immuno-oncology pipeline
Recent news mentioning T-Cell Engager
- — Abogen Announces Licensing and Option Agreement with Novartis to Advance mRNA-Encoded T-Cell Engager and other potential RNA programs
- — Abogen Announces Licensing and Option Agreement with Novartis to Advance mRNA-Encoded T-Cell Engager and other potential RNA programs
- — Amberstone Biosciences and Henlius Enter into Collaboration and License Agreement for Conditionally Activated T-Cell Engagers for Solid Tumors